Gene expression profiling: Changing face of breast cancer classification and management

Gene Expression

Volumn 15, Issue 3, 2011, Pages 105-115

  Wesolowski, Robert ^a   Ramaswamy, Bhuvaneswari ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Biologic behavior; Breast cancer; Breast cancer subtypes; Classification; Gene expression profiling

Indexed keywords

ANTHRACYCLINE; COMPLEMENTARY DNA; CRK ASSOCIATED SUBSTRATE PROTEIN; CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 7; CYTOKERATIN 8; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; FLUOROURACIL; INTERLEUKIN 17 RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; PACLITAXEL; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST BIOPSY; BREAST CANCER; BREAST EPITHELIUM; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER MORPHOLOGY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; HOMEOBOX; HUMAN; IN SITU HYBRIDIZATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE MANAGEMENT; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2;

EID: 81055126400     PISSN: 10522166     EISSN: None     Source Type: Journal    
DOI: 10.3727/105221611X13176664479241     Document Type: Review

References (63)

1. Albain, K. S.; Barlow, W. E.; Shak, S.; Hortobagyi, G. N.; Livingston, R. B.; Yeh, I. T.; Ravdin, P.; Bugarini, R.; Baehner, F. L.; Davidson, N. E.; Sledge, G. W.; Winer, E. P.; Hudis, C.; Ingle, I. N.; Perez, E. A.; Pritchard, K. I.; Shepherd, L.; Gralow, I. R.; Yoshizawa, C.; Allred, D. C.; Osborne, C. K.; Hayes, D. F. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 11:55-65; 2010.
2. Albain, K. S.; Carey, L.; Gradishar, W. J.; Gralow, J. R.; Lipton, A.; Rugo, H.; Tripathy, D.; Peck, S.; Abair, T.; Pegram, M. Proceedings of the First Global Workshop on Breast Cancer: Pathways to the evaluation and clinical development of novel agents for breast cancer. Clin. Breast Cancer 10:421-439; 2010.
3. Albanell, J.; González, A.; Ruiz-Borrego, M.; Alba, E.; García-Saenz, J. A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limon, M. L.; Muñoz, A. S.; Martín, M.; Tusquets, I.; Rojo, F.; Colomer, R.; Faull, I.; Lluch, A. Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann. Oncol. in press; 2011.
4. Alizadeh, A. A.; Ross, D. T.; Perou, C. M.; van de Rijn, M. Towards a novel classification of human malignancies based on gene expression patterns. J. Pathol. 195:41-52; 2001.
5. Alli, E.; Sharma, V. B.; Sunderesakumar, P.; Ford, J. M. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 69:3589-3596; 2009.
6. Alwine, J. C.; Kemp, D. J.; Stark, G. R. Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. Proc. Nail. Acad. Sci. USA 74:5350-5354; 1977.
7. Ayers, M.; Symmans, W. F.; Stec, I.; Damokosh, A. I.; Clark, E.; Hess, K.; Lecocke, M.; Metivier, J.; Booser, D.; Ibrahim, N.; Valero, V.; Royce, M.; Arun, B.; Whitman, G.; Ross, J.; Sneige, N.; Hortobagyi, G. N.; Pusztai, L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 1522:2284-2293; 2004.
8. Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2:104-107; 1896.
9. Ben-Porath, I.; Thomson, M. W.; Carey, V. J.; Ge, R.; Bell, G. W.; Regev, A.; Weinberg, R. A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40:499-507; 2008.
10. Brody, L. C. Treating cancer by targeting a weakness. N. Engl. J. Med. 353:949-950; 2005.
11. Bueno-de-Mesquita, J. M.; van Harten, W. H.; Retel, V. P.; van't Veer, L. J.; van Dam, F. S.; Karsenberg, K.; Douma, K. F.; van Tinteren, H.; Peterse, J. L.; Wesseling, J.; Wu, T. S.; Atsma, D.; Rutgers, E. J.; Brink, G.; Floore, A. N.; Glas, A. M.; Roumen, R. M.; Bellot, F. E.; van Krimpen, C.; Rodenhuis, S.; van de Vijver, M. J.; Linn, S. C. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: A prospective community-based feasibility study (RASTER). Lancet Oncol. 8:1079-1087; 2007.
12. Buyse, M.; Loi, S.; van't Veer, L.; Viale, G.; Delorenzi, M.; Glas, A. M.; d'Assignies, M. S.; Bergh, J.; Lidereau, R.; Ellis, P.; Harris, A.; Bogaerts, J.; Therasse, P.; Floore, A.; Amakrane, M.; Piette, F.; Rutgers, E.; Sotiriou, C.; Cardoso, F.; Piccart, M. J. TRANS-BIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node negative breast cancer. J. Natl. Cancer Inst. 98:1183-1192; 2006.
13. Buzdar, A. U. Advances in endocrine treatments for post-menopausal women with metastatic and early breast cancer. Oncologist 8:335-341; 2003.
14. Carey, L.; Winer, E.; Viale, G.; Cameron, D.; Gianni, L. Triple-negative breast cancer: Disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7:683-692; 2010.
15. Chin, K.; DeVries, S.; Fridlyand, J.; Spellman, P. T.; Roydasgupta, R.; Kuo, W. L.; Lapuk, A.; Neve, R. M.; Qian, Z.; Ryder, T.; Chen, F.; Feiler, H.; Tokuyasu, T.; Kingsley, C.; Dairkee, S.; Meng, Z.; Chew, K.; Pinkel, D.; Jain, A.; Ljung, B. M.; Esserman, L.; Albertson, D. G.; Waldman, F. M.; Gray, J. W. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 10:529-541; 2006.
16. Cobleigh, M. A.; Tabesh, B.; Bitterman, P.; Baker, J.; Cronin, M.; Liu, M. L.; Borchik, R.; Mosquera, J. M.; Walker, M. G.; Shak, S. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. Cancer Res. 11:8623-8631; 2005.
17. Cronin, M.; Pho, M.; Dutta, D.; Stephans, J. C.; Shak, S.; Kiefer, M. C.; Esteban, J. M.; Baker, J. B. Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am. J. Pathol. 164:35-42; 2004.
18. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717; 2005.
19. Eisen, M. B.; Brown, P. O. DNA arrays for analysis of gene expression. Methods Enzymol. 303:179-205; 1999.
20. Eisen, M. B.; Spellman, P. T.; Brown, P. O.; Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Nail. Acad. Sci. USA 95:14863-14868; 1998.
21. Ellis, M. J.; Suman, V. J.; Hoog, J.; Lin, L.; Snider, J.; Prat, A.; Parker, J. S.; Luo, J.; Deschryver, K.; Allred, D. C.; Esserman, L. J.; Unzeitig, G. W.; Margenthaler, J.; Babiera, G. V.; Marcom, P. K.; Guenther, J. M.; Watson, M. A.; Leitch, M.; Hunt, K.; Olson, J. A. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. J. Clin. Oncol. 29:2342-2349; 2011.
22. Esteban, J.; Baker, J.; Cronin, M.; Liu, M. L.; Llamas, M. G.; Walker, M. G.; Mena, R.; Shak, S. Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue. Prog. Proc. Am. Soc. Clin. Oncol. 22:850; 2003.
23. Fan, C.; Oh, D. S.; Wessels, L.; Weigelt, B.; Nuyten, D. S.; Nobel, A. B.; van't Veer, L. J.; Perou, C. M. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355:560-569; 2006.
24. Finak, G.; Bertos, N.; Pepin, F.; Sadekova, S.; Souleimanova, M.; Zhao, H.; Chen, H.; Omeroglu, G.; Meterissian, S.; Omeroglu, A.; Hallett, M.; Park, M. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14:518-527; 2008.
25. Geyer, C. E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C. G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campne, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S. D.; Stein, S.; Cameron, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355:2733-2743; 2006.
26. Goetz, M. P.; Suman, V. J.; Ingle, J. N.; Nibbe, A. M.; Visscher, D. W.; Reynolds, C. A.; Lingle, W. L.; Erlander, M.; Ma, X. J.; Sgroi, D. C.; Perez, E. A.; Couch, F. J. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res. 12:2080-2087; 2006.
27. Goldstein, L. J.; Gray, R.; Badve, S.; Childs, B. H.; Yoshizawa, C.; Rowley, S.; Shak, S.; Baehner, F. L.; Ravdin, P. M.; Davidson, N. E.; Sledge, Jr., G. W.; Perez, E. A.; Shulman, L. N.; Martino, S.; Sparano, J. A. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical cinicopathologic features. J. Clin. Oncol. 26:4063-4071; 2008.
28. Habel, L.A.; Shak, S.; Jacobs, M. K.; Capra, A.; Alexander, C.; Pho, M.; Baker, J.; Walker, M.; Watson, D.; Hackett, J.; Blick, N. T.; Greenberg, D.; Fehrenbacher, L.; Langbolz, B.; Quesenberry, C. P. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8:R25; 2006.
29. Haibe-Kains, B.; Desmedt, C.; Piette, F.; Buyse, M.; Cardoso, F.; Van't Veer, L.; Piccart, M.; Bontempi, G.; Sotiriou, C. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 9:394; 2008.
30. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; Hayes, D. F.; Bast, Jr., R. C. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. I. Clin. Oncol. 25:5287-5312; 2007.
31. Hess, K. R.; Anderson, K.; Symnians, W. F.; Valero, V.; Ibrahim, N.; Mejia, J. A.; Booser, D.; Theriault, R. L.; Buzdar, A. U.; Dempsey, P. J.; Rouzier, R.; Sneige, N.; Ross, J. S.; Vidaurre, T.; Gómez, H. L.; Hortobagyi, G. N.; Pusztai, L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24:4236-4244; 2006.
32. Iwamoto, T.; Bianchini, G.; Booser, D.; Qi, Y.; Coutant, C.; Shiang, C. Y.; Santarpia, L.; Matsuoka, J.; Hortobagyi, G. N.; Symmans, W. F.; Holmes, F. A.; O'Shaugbnessy, J.; Hellerstedt, B.; Pippen, J.; Andre, F.; Simon, R.; Pusztai, L. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J. Natl. Cancer Inst. 103:264-272; 2011.
33. Jansen, M. P.; Sieuwerts, A. M.; Look, M. P.; Ritstier, K.; Meijer-van Gelder, M. E.; van Staveren, I. L.; Klijn, J. G.; Foekens, J. A.; Berns, E. M. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: A retrospective study. J. Clin. Oncol. 25:662-668; 2007.
34. Liu, R.; Wang, X.; Chen, G. Y.; Dalerba, P.; Gurney, A.; Hoey, T.; Sherlock, G.; Lewicki, J.; Shedden, K.; Clarke, M. F. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356:217-226; 2007.
35. Lockhart, D. J.; Dong, H.; Byrne, M. C.; Follettie, M. T.; Gallo, M. V.; Chee, M. S.; Mittmann, M.; Wang, C.; Kobayashi, M.; Horton, H.; Brown, E. L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nature Biotechnol. 14: 1675-1680; 1996.
36. Loi, S.; Haibe-Kains, B.; Desmedt, C.; Lallemand, F.; Tutt, A. M.; Gillet, C.; Ellis, P.; Harris, A.; Bergh, J.; Foekens, J. A.; Klijn, J. G.; Larsimont, D.; Buyse, M.; Bontempi, G.; Delorenzi, M.; Piccart, M. J.; Sotiriou, C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25:1239-1246; 2007.
37. Ma, X. J.; Hilsenbeck, S. G.; Wang, W.; Ding, L.; Sgroi, D. C.; Bender, R. A.; Osborne, C. K.; Allred, D. C.; Erlander, M. G. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J. Clin. Oncol. 24:4611-4619; 2006.
38. Ma, X. J.; Salunga, R.; Dahiya, S.; Wang, W.; Carney, E.; Durbecq, V.; Harris, A.; Goss, P.; Sotiriou, C.; Erlander, M.; Sgroi, D. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res. 14:2601-2608; 2008.
39. Miller, T. E.; Ghoshal, K.; Ramaswamy, B.; Roy, S.; Datta, J.; Shapiro, C. L.; Jacob, S.; Majumder, S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 283:29897-29903; 2008.
40. Paik, S.; Shak, S.; Tang, G. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14. Breast Cancer Res. Treat. 82:A16; 2003.
41. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F. L.; Walker, M. G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E. R.; Wickerham, D. L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351:2817-2826; 2004.
42. Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim, W.; Cronin, M.; Baehner, F. L.; Watson, D.; Bryant, J.; Costantino, J. P.; Geyer, C. E.; Wickerham, D. L.; Wolmark, N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24:3726-3734; 2006.
43. Parker, J. S.; Mullins, M.; Cheang, M. C.; Leung, S.; Voduc, D.; Vickery, T.; Davies, S.; Fauron, C.; He, X.; Hu, Z.; Quackenbush, J. F.; Stijleman, I. J.; Palazzo, J.; Marron, J. S.; Nobel, A. B.; Mardis, E.; Nielsen, T. O.; Ellis, M. J.; Perou, C. M.; Bernard, P. S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27:1160-1167; 2009.
44. Perou, C. M.; Jeffrey, S. S.; van de Rijn, M.; Rees, C. A.; Eisen, M. B.; Ross, D. T.; Pergamenschikov, A.; Williams, C. F.; Zhu, S. X.; Lee, J. C.; Lashkari, D.; Shalon, D.; Brown, P. O.; Botstein, D. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA 96:9212-9217; 1999.
45. Perou, C. M.; Sørlie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Rees, C. A.; Pollack, J. R.; Ross, D. T.; Johnsen, H.; Akslen, L. A.; Huge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S. X.; Lønning, P. E.; Børresen-Dale, A. L.; Brown, P. O.; Botstein, D. Molecular portraits of human breast tumors. Nature 406:747-752; 2000.
46. Pinder, M. C.; Buzdar, A. U. Endocrine therapy for breast cancer. In Hunt, K. K.; Robb, G. L.; Strom, E. A.; Ueno, N. T., eds. Breast cancer, 2nd ed. (M.D. Anderson Cancer Care Series). New York: Springer; 2008:411-434.
47. Prat, A.; Parker, J. S.; Karginova, O.; Fan, C.; Livasy, C.; Herschkowitz, J. I.; He, X.; Perou, C. M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12:R68; 2010.
48. Romond, E. H.; Perez, E. A.; Bryant, J.; Suman, V. J.; Geyer, C. E.; Davidson, N. E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P. A.; Swain, S. M.; Pisansky, T. M.; Fehrenbacher, L.; Kutteh, L. A.; Vogel, V. G.; Visscher, D. W.; Yothers, G.; Jenkins, R. B.; Brown, A. M.; Dakhil, S. R.; Mamounas, E. P.; Lingle, W. L.; Klein, P. M.; Ingle, J. N.; Wolmark, N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353:1673-1684; 2005.
49. Rouzier, R.; Perou, C. M.; Symmans, W. F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K. R.; Stec, J.; Ayers, M.; Wagner, P.; Morandi, P.; Fan, C.; Rabiul, I.; Ross, J. S.; Hortobagyi, G. N.; Pusztai, L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11:5678-5685; 2005.
50. Sarrió, D.; Rodriguez-Pinilla, S. M.; Hardisson, D.; Cano, A.; Moreno-Bueno, G.; Palacios, J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68:989-997; 2008.
51. Scholl, S. M.; Pierga, J. Y.; Asselain, B. Breast tumours response to primary chemotherapy predicts local and distant control as well as survival. Eur. J. Cancer 31A:1969-1995; 1995.
52. Simpson, P. T.; Reis-Filho, J. S.; Gale, T.; Lakhani, S. R. Molecular evolution of breast cancer. J. Pathol. 205:248-254; 2005.
53. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182; 1987.
54. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-792; 2001.
55. Smith, I.; Procter, M.; Gelber, R. D.; Guillaume, S.; Feyereislova, A.; Dowsett, M.; Goldhirsch, A.; Untch, M.; Mariani, G.; Baselga, J.; Kaufmann, M.; Cameron, D.; Bell, R.; Bergh, J.; Coleman, R.; Wardley, A.; Harbeck, N.; Lopez, R. I.; Mallmann, P.; Gelmon, K.; Wilcken, N.; Wist, E.; Sánchez Rovira, P.; Piccart-Gebhart, M. J.; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36; 2007.
56. Sørlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Eystein Lønning, P.; Børresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Nail. Acad. Sci. USA 98:10869-10874; 2001.
57. Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J. S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; Demeter, J.; Perou, C. M.; Lønning, P. E.; Brown, P. O.; Børresen-Dale, A. L.; Botstein, D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100:8418-8423; 2003.
58. Sotiriou, C.; Pusztai, L.; Gene-expression signatures in breast cancer. N. Engl. J. Med. 360:790-800; 2009.
59. Subramanian, A.; Tamayo, P.; Mootha, V. K.; Mukherjee, S.; Ebert, B. L.; Gillette, M. A.; Paulovich, A.; Pomeroy, S. L.; Golub, T. R.; Lander, E. S.; Mesirov, J. P. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102:15545-15550; 2005.
60. van de Vijver, M. J.; He, Y. D.; van't Veer, L. J.; Dai, H.; Hart, A. A.; Voskuil, D. W.; Schreiber, G. J.; Peterse, J. L.; Roberts, C.; Marton, M. J.; Parrish, M.; Atsma, D.; Witteveen, A.; Glas, A.; Delahaye, L.; van der Velde, T.; Bartelink, H.; Rodenhuis, S.; Rutgers, E. T.; Friend, S. H.; Bernards, R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009; 2002.
61. van't Veer, L. J.; Dai, H.; van de Vijver, M. J.; He, Y. D.; Hart, A. A.; Mao, M.; Peterse, H. L.; van der Kooy, K.; Marton, M. J.; Witteveen, A. T.; Schreiber, G. J.; Kerkhoven, R. M.; Roberts, C.; Linsley, P. S.; Bernards, R.; Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536; 2002.
62. Young, R. A. Biomedical discovery with DNA arrays. Cell 102:9-15; 2000.
63. Zhao, J. J.; Lin, J.; Yang, H.; Kong, W.; He, L.; Ma, X.; Coppola, D.; Cheng, J. Q. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283:31079-31086; 2008.